Cabaletta Bio, Inc. Common Stock
$2.55
-$0.03 (-1.16%)
$2.52Day Range$2.61
Key Statistics
Market Cap
$437.43M
Shares Outstanding
169.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 25, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$2.55
Day High
$2.61
Day Low
$2.52
Volume
12.48M
VWAP
$2.56
Prev Close
$2.58
Transactions
--
Acc. Volume
--
About Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836158 employees2929 ARCH STREET, PHILADELPHIA, PA, 19104(267) 759-3100IPO Oct 25, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001759138
- Composite FIGI
- BBG00MJ3BKW2
- Share Class FIGI
- BBG00MJ3BKX1
- Ticker Root
- CABA
- SIC Code
- 2836
About Cabaletta Bio, Inc. Common Stock (CABA) Stock
Cabaletta Bio, Inc. Common Stock (CABA) closed the 2026-09-18 session at $2.55, down 1.16% versus the previous close (-0.03). The stock opened at $2.55 and traded between $2.52 and $2.61 during that session. Session trading volume was 12.5M shares. The volume-weighted average price (VWAP) is $2.56.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Cabaletta Bio, Inc. Common Stock has a market capitalization of $437.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CABA is listed on the XNAS exchange. The company employs approximately 158 people. Cabaletta Bio, Inc. Common Stock is headquartered in PHILADELPHIA, PA. The recorded listing date is 2019-10-25.
On this page you can find market CABA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.